GL1X · GenesisL1 explorer

Research workbench

Crystal structure of HCV NS5B 1B with (1,1-dioxo-2H-[1,2, 4]BENZOTHIADIAZIN-3-yl) AZOLO[1,5-A]PYRIMIDINE derivative

Analyse Crystal structure of HCV NS5B 1B with (1,1-dioxo-2H-[1,2… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
3H98
Type
protein
Length
1,110 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
RNA-directed RNA polymerase
EC
2.7.7.48
UniProt
P26663
Ligands
B5P
Pockets
13 · best druggability 0.80

Structure

x-ray diffraction · 2 distinct chains · 48% helix, 15% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ARNA-directed RNA polymerase (EC 2.7.7.48)protein55148% helix, 15% strandP26663
BRNA-directed RNA polymerase (EC 2.7.7.48)protein55948% helix, 15% strandP26663

Ligands and binding sites

  • B5P · N-{3-[5-hydroxy-8-(3-methylbutyl)-7-oxo-7,8-dihydroimidazo[1,2-a]pyrimidin-6-yl]-1,1-dioxido-4H-1,2,4-benzothiadiazin-7-yl}methanesulfonamide · ligand · 2 copies · chains A, B
  • GOL · Glycerol · additive · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

13 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111160.800.8185B5P, GOL
210790.800.8180B5P
35680.690.7854empty
42660.670.8327empty
51140.480.8020empty

Interfaces

1 interface between chains.

  • A–B · 595 Ų buried · 5 hydrogen bonds · protein-protein

Compared structures

  • 3H98 · Crystal structure of HCV NS5b 1b with (1,1-dioxo-2H-[1,2,4]benzothiadiazin-3-yl)… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.